drugset
Drugs / aH5N1c
last change Jul 2019 re-read 3 minutes ago

aH5N1c

Vaccine

Developed for
avian influenza
Investigated by
Biomedical Advanced Research and Development Authority · Department of Health and Human Services · Novartis Vaccines · Seqirus

Trials 2

today NCT02839330 · Ph 3 NCT01776554 · Ph 2
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT01776554 Jan → Jun 2013 avian influenza Novartis Vaccines Completed No outcome recorded
Phase 31 trial
Phase 3 NCT02839330 Jul 2016 → Oct 2017 avian influenza Seqirus Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as aH5N1c “BACKGROUND: A/H5N1 influenza virus has significant pandemic potential, and vaccination is the main prophylactic measure. This phase 2, randomized, observer-blind, multicenter...” PMID 31194712 ↗ Jul 2019
1

NCT02839330 ↗
Modality Vaccine “two MF59-adjuvanted, cell culture-derived H5N1 (aH5N1c) vaccine formulations” PMID 31194712 ↗ Jul 2019
Route Intramuscular “Intramuscular (IM) administration” NCT02839330 ↗